Aurobindo Pharma has officially concluded its share buyback program, extinguishing 5,423,728 equity shares. The company bought back these shares at a price of ₹1,475 per share, resulting in an aggregate payout of up to ₹800 crore. This strategic move was executed through the tender offer route, reducing the total issued and subscribed equity capital from 58,08,01,623 shares to 57,53,77,895 shares.
Buyback Details and Capital Reduction
Aurobindo Pharma has finalized the extinguishment of 5,423,728 equity shares. These shares were acquired by the company at a premium price of ₹1,475 per share. Following the completion of this buyback, the company’s total issued and subscribed share capital has been adjusted downward to 57,53,77,895 shares, each with a face value of ₹1.
Impact on Shareholding Pattern
The buyback has resulted in a shift in the company’s shareholding structure. The promoter and promoter group now hold 29,85,22,726 equity shares, representing 51.88% of the total share capital. The non-promoter category, which includes foreign investors, financial institutions, and retail shareholders, holds the remaining 27,68,55,169 equity shares, accounting for 48.12% of the company post-extinguishment.
Execution and Compliance
The extinguishment process was completed on May 14, 2026, for all shares held in dematerialized form. Confirmations from the National Securities Depository Limited (NSDL) and Central Depository Services (India) Limited (CDSL) were received on that date, ensuring that all 5,423,728 shares were successfully debited and destroyed. This corporate action was verified by the company’s registrar, KFin Technologies Limited, and audited by independent secretarial auditors to ensure full compliance.
Source: BSE
